Thalidomide is notorious for causing death and disability but it – and its derivatives – are proving useful for conditions such as leprosy.
The thalidomide tragedy changed how medicines are viewed during pregnancy – not only by pregnant women, but also the wider community.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can’t always protect us from harm.
Thalidomide was responsible for one of the biggest drug disasters in history. It is making a comeback. But is Africa equipped to handle this controversial drug?
Reactions to the thalidomiders’ difference contributed – and continue to contribute – to their negative well-being and deteriorating health.
Decades have passed and yet the issue of financial compensation for the remaining “survivors” of the thalidomide tragedy has, in many instances, remained unresolved.
Journalist-turned-lawyer Michael Magazanik worked on recent Australian thalidomide lawsuits. As part of our series on the drug, he spoke to Ian Freckelton about the book he wrote, based on the case.
Thalidomide’s manufacturer, Chemie Grünenthal, marketed the drug as safe for pregnant women despite reports it was causing malformations in newborns. Why such blatant denial?
Sir Harold Evans talks to Richard Sambrook about The Sunday Times’ moral campaign against thalidomide’s manufacturers, the fight for political validation and the rise of investigative journalism.
Thalidomide was developed in an era of widespread enthusiasm – but little critical attention – for pharmaceutical therapies.
Thalidomide was marketed as a safe, sleep-inducing drug, but when taken during pregnancy it could cause severe birth defects.
Thalidomide caused thousands of spontaneous abortions and left more than 10,000 children severely disabled. What guarantee is there that the same thing can’t occur again today?
Documents reveal thalidomide’s manufacturer was warned about possible harms as early as 1956.